Ignite Creation Date:
2024-05-05 @ 12:10 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00268970
Status:
COMPLETED
Last Update Posted:
2012-04-30
First Post:
2005-12-22
Brief Title:
Satraplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer
Sponsor:
Agennix
Organization:
Agennix
Study Overview
Official Title:
Phase 2 Trial of First-Line Therapy With Satraplatin and Paclitaxel in Patients With Unresectable Stage III or IV Non-small Cell Lung Cancer NSCLC
Status:
COMPLETED
Status Verified Date:
2012-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this trial is to study the combination regimen of satraplatin and paclitaxel in the first-line treatment of patients with advanced non-small cell lung cancer NSCLC
Detailed Description:
This trial is designed to study the efficacy and safety of a novel oral platinum analog satraplatin in combination with another chemotherapy drug paclitaxel for the first line of treatment patients who have not received chemotherapy for disease that has metastasized of patients with advanced NSCLC
WHAT IS SATRAPLATIN
Satraplatin is a member of the platinum-based class of chemotherapy drugs Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies Unlike the currently marketed platinum-based drugs satraplatin can be given orally
WHAT IS SATRAPLATIN
Satraplatin is a member of the platinum-based class of chemotherapy drugs Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies Unlike the currently marketed platinum-based drugs satraplatin can be given orally
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None